IRWD logo

Ironwood Pharmaceuticals Inc. (IRWD)

$4.87

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on IRWD

Market cap

$806232201

EPS

0.92

P/E ratio

4.8

Price to sales

1.62

Dividend yield

--

Beta

0.258974

Price on IRWD

Previous close

$4.85

Today's open

$4.83

Day's range

$4.77 - $4.89

52 week range

$2.95 - $5.78

Profile about IRWD

CEO

Thomas McCourt

Employees

100

Headquarters

Boston, MA

Exchange

Nasdaq Global Select

Shares outstanding

165550760

Issue type

Common Stock

IRWD industries and sectors

Healthcare

Pharmaceuticals

News on IRWD

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2026 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt - CEO & Director Tammi Gaskins - Senior Vice President & Chief Commercial Officer Jeffrey Silber - Chief Medical Officer, Head of Research & Drug Development Ronald Silver - Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Jeff Ruberti - Chief Strategy Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Nicholas Mattiacci Tom Rosenfeld Presentation Operator Hello, everyone. My name is Megan, and I will be your conference operator today.

news source

Seeking Alpha • Nov 6, 2026

news preview

IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock Up

Ironwood's Q3 earnings beat estimates, lifting shares 6.9%, as stronger Linzess sales expectations and profitability drive a higher 2026 outlook.

news source

Zacks Investment Research • Nov 6, 2026

news preview

What Ironwood Pharmaceuticals (IRWD) Said on Its Q3 Earnings Call

Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the gastrointestinal drug's performance.

news source

MarketBeat • Nov 5, 2026

news preview

Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas.

news source

Business Wire • Nov 5, 2026

news preview

Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its third quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 5, 2026. Individuals interested in participating in the call should dial (833) 461-5787 (U.S.) or (585) 542-9983 (international) using conference ID number and event passcode 496523279. To access the webcast, please visit the Investors & Media section of Ironwood's website at ww.

news source

Business Wire • Oct 28, 2026

news preview

Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.

news source

Business Wire • Oct 16, 2026

news preview

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?

IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.

news source

Zacks Investment Research • Oct 7, 2026

news preview

Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy

Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.

news source

Seeking Alpha • Oct 7, 2026

news preview

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?

Precigen's Papzimeos and Ironwood's Linzess are driving growth, but competition, pipeline progress and single-product reliance shape each biotech's outlook.

news source

Zacks Investment Research • Sep 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ironwood Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Ironwood Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in IRWD on M1